Can a Cancer-Fighting virus shrink resistant tumors?

NCT ID NCT07748117

Not yet recruiting Disease control Sponsor: GeneSail Biotech (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental virus called GO321, which is designed to infect and destroy cancer cells. The study involves adults with advanced solid tumors that have not responded to standard treatments. Participants receive GO321 as an injection directly into the tumor or body cavity, and researchers will monitor safety, side effects, and any signs that the virus is fighting the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GO321, a recombinant oncolytic virus injected directly into tumors or body cavities
What this could lead to: If successful, this could offer a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. The virus may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR MALIGNANCIES

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.